

A6
cont

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

47. A protein produced according to a process comprising:

A7

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

57. A protein produced according to a process comprising:

A8

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

67. A protein produced according to a process comprising:

A9

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

77. A protein produced according to a process comprising:

A10

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

87. A protein produced according to a process comprising:

A11

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

Please add new claims 96, 97, 98, and 99 as follows:

96. (New) A method of treating a condition characterized by P- or E-selectin mediated intercellular adhesion comprising administering a therapeutically effective amount of a composition of claim 7 to a mammalian subject.

A12

97. (New) A method of treating a condition characterized by P- or E-selectin mediated intercellular adhesion comprising administering a therapeutically effective amount of a composition of claim 12 to a mammalian subject.

98. (New) The method of claims 96 or 97 wherein said condition characterized by P- or E-selectin mediated intercellular adhesion is selected from the group consisting of: myocardial infarction, vessel restenosis, thrombosis, bacterial or viral infection, metastatic conditions, inflammatory disorders such as arthritis, acute